Processa Pharmaceuticals Inc (PCSA) is destined for greater heights as its last quarter sales were 0 K

A new trading day began on Monday, with Processa Pharmaceuticals Inc (NASDAQ: PCSA) stock price up 4.49% from the previous day of trading, before settling in for the closing price of $0.2. PCSA’s price has ranged from $0.15 to $3.10 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

A company in the Healthcare sector has jumped its sales by 22.65% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 81.52%. With a float of $22.73 million, this company’s outstanding shares have now reached $26.19 million.

In an organization with 10 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.

Processa Pharmaceuticals Inc (PCSA) Insider Updates

As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Processa Pharmaceuticals Inc is 13.24%, while institutional ownership is 0.65%. The most recent insider transaction that took place on Jan 27 ’25, was worth 9,889. In this transaction Director of this company bought 12,400 shares at a rate of $0.80, taking the stock ownership to the 12,400 shares. Before that another transaction happened on Jan 27 ’25, when Company’s Chief Executive Officer bought 87,200 for $0.80, making the entire transaction worth $69,542. This insider now owns 87,200 shares in total.

Processa Pharmaceuticals Inc (PCSA) Performance Highlights and Predictions

According to the Wall Street analysts, stocks earnings will be around 81.52% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 42.13% during the next five years compared to 22.65% growth over the previous five years of trading.

Processa Pharmaceuticals Inc (NASDAQ: PCSA) Trading Performance Indicators

Here are Processa Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.93.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.08, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.54 in one year’s time.

Technical Analysis of Processa Pharmaceuticals Inc (PCSA)

Let’s dig in a bit further. During the last 5-days, its volume was 8.75 million. That was inferior than the volume of 9.26 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 3.36%.

During the past 100 days, Processa Pharmaceuticals Inc’s (PCSA) raw stochastic average was set at 8.66%, which indicates a significant increase from 2.52% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 239.07% in the past 14 days, which was higher than the 134.95% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $0.2618, while its 200-day Moving Average is $0.7197. However, in the short run, Processa Pharmaceuticals Inc’s stock first resistance to watch stands at $0.2141. Second resistance stands at $0.2233. The third major resistance level sits at $0.2298. If the price goes on to break the first support level at $0.1984, it is likely to go to the next support level at $0.1919. Assuming the price breaks the second support level, the third support level stands at $0.1827.

Processa Pharmaceuticals Inc (NASDAQ: PCSA) Key Stats

With a market capitalization of 5.37 million, the company has a total of 11,884K Shares Outstanding. Currently, annual sales are 0 K while annual income is -11,850 K. The company’s previous quarter sales were 0 K while its latest quarter income was -2,830 K.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.